MediciNova
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- -
- Market Cap
- $71.6M
- Introduction
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 255
- Registration Number
- NCT01982942
- Locations
- 🇺🇸
University at Buffalo, The State University of New York, Buffalo, New York, United States
🇺🇸Cornell Medical College, New York, New York, United States
🇺🇸University of Virginia Charlottesville, Charlottesville, Virginia, United States
Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients
- Conditions
- Interventions
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 19
- Registration Number
- NCT01551316
- Locations
- 🇺🇸
Central Texas Health Research, New Braunfels, Texas, United States
🇺🇸Sylvana Research Associates, San Antonio, Texas, United States
Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2015-05-13
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 48
- Registration Number
- NCT01013142
- Locations
- 🇺🇸
California Research Medical Group, INC, Fullerton, California, United States
🇺🇸Dedicated Phase I, Phoenix, Arizona, United States
🇺🇸Vita Research Solutions & Medical Center, Inc., Tamarac, Florida, United States
Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 176
- Registration Number
- NCT00838591
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Albert Einstein Healthcare Network, Philadelphia, Pennsylvania, United States
🇺🇸Baystate Medical Center, Springfield, Massachusetts, United States
Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma
- Conditions
- Interventions
- First Posted Date
- 2008-05-23
- Last Posted Date
- 2011-10-07
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 29
- Registration Number
- NCT00683449
- Locations
- 🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States
🇺🇸Maricopa Medical Center; Dept. of Emergency Medicine, Phoenix, Arizona, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2011-12-19
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 17
- Registration Number
- NCT00679263
- Locations
- 🇺🇸
PRA International, Lenexa, Kansas, United States
🇺🇸Northeast Medical Research Associates, North Dartmouth, Massachusetts, United States
🇺🇸Clinical Research of the Ozarks, Rolla, Missouri, United States
Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis
- Conditions
- Interventions
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 296
- Registration Number
- NCT00295854
- Locations
- 🇺🇸
William Beaumont Hospital, Royal Oak, Michigan, United States
🇺🇸Adult and Pediatric Urology, Plantation, Florida, United States
🇺🇸Georgis Patsias, MD., PA, Wellington, Florida, United States